Jubilant Ingrevia Ltd. (JUBLINGREA) AI Stock Analysis

• Market Cap: ₹109.29B
• Dividend Yield: 0.74%
• Average Volume (3M): 13.09K
• Price to Earnings (P/E): 37.6
• Beta (1Y): 0.95
• Revenue Growth: 3.80%
• EPS Growth: 64.94%
• Country: IN
• Employees: 2,283
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): 4.40
• Shares Outstanding: 159,281,140
• 10 Day Avg. Volume: 10,350
• 30 Day Avg. Volume: 13,091
• PEG Ratio: 1.10
• Price to Book (P/B): 3.53
• Price to Sales (P/S): 2.47
• P/FCF Ratio: 72.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹722.00 ▼(-0.55% Downside)

Jubilant Ingrevia Ltd. demonstrates strong financial performance with stable margins and profitability, which is the most significant factor in its overall score. However, technical analysis indicates a bearish trend, and the valuation suggests the stock is relatively expensive, both of which weigh down the overall score.

Positive Factors

Revenue Growth

Jubilant Ingrevia's consistent revenue growth and stable margins indicate a strong market position and effective business model, supporting long-term profitability.

Cash Generation

Strong cash generation enhances financial flexibility, enabling Jubilant Ingrevia to invest in growth opportunities and manage debt effectively over the long term.

Equity Position

A solid equity position with moderate leverage supports financial stability, allowing Jubilant Ingrevia to withstand economic fluctuations and pursue strategic initiatives.

Negative Factors

Revenue Fluctuations

Revenue fluctuations can impact financial predictability and planning, posing risks to sustained growth and operational stability if not managed effectively.

Increasing Liabilities

Rising liabilities may strain financial resources and limit investment capacity, potentially affecting Jubilant Ingrevia's ability to capitalize on growth opportunities.

Capital Expenditure Challenges

Challenges in managing capital expenditures can hinder long-term growth and operational efficiency, impacting Jubilant Ingrevia's competitive positioning.

Jubilant Ingrevia Ltd. Business Overview & Revenue Model

Company Description

Jubilant Ingrevia Limited provides life science products and solutions in India and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment offers specialty ingredients, fine chemicals, crop protection chemicals, and custom development and manufacturing services. The Nutrition & Health Solutions segment provides nutrition and health ingredients, animal nutrition and health solutions, and human nutrition and health solutions. The Life Science Chemicals offers life science ingredients and specialty ethanol. The company also offers pyridine and picolines, cyanopyridines, piperidines, acetyl pyridines, amino pyridines, halo pyridines, pyridine aldehydes, metal complexes, amino pyridines, halogenated pyridines, quaternary salts, alkyl pyridines, vitamin B3 and picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, absolute alcohol, ethanol, biocompost, CO2 and ETO mixtures. In addition, it provides route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company offers vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, nutrition, agrochemical, consumer, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is based in Noida, India.

How the Company Makes Money

Jubilant Ingrevia generates revenue through several key streams, primarily by producing and selling specialty chemicals and life science ingredients. The company earns significant income from its pharmaceutical segment, where it supplies APIs and intermediates to major global pharmaceutical companies. Additionally, it derives revenue from its agriculture segment by providing crop protection chemicals and agrochemical products. The food segment contributes to earnings through the sale of food additives and ingredients. Strategic partnerships with leading firms in various industries enhance its market position and contribute to stable revenue growth. The company also invests in R&D to innovate and expand its product offerings, which can lead to increased sales and market share.

Jubilant Ingrevia Ltd. Financial Statement Overview

Summary

Jubilant Ingrevia Ltd. exhibits strong financial health with positive revenue and profit growth trends, stable margins, and a solid equity foundation. While some fluctuations in revenue and cash flow management present challenges, the company's operational efficiency and profitability position it well in the biotechnology industry. Continued attention to leverage and cash flow generation will be crucial to sustaining growth.

Income Statement

The income statement shows a consistent growth trajectory in revenue over the years, with a noticeable increase in gross and net profit margins. However, there was a dip in revenue in 2024, followed by recovery in 2025. The EBIT and EBITDA margins have been stable, indicating efficient operations. Overall, the company demonstrates a strong ability to generate profits, though fluctuations in revenue growth present moderate risk.

Balance Sheet

The balance sheet reveals a solid equity position with a reasonable debt-to-equity ratio indicating moderate leverage. Return on equity has been healthy, supporting profitability. However, increasing total liabilities highlight potential risk if revenue does not continue to grow. The equity ratio is strong, suggesting good financial stability.

Cash Flow

The company's cash flow statement shows robust operating cash flow and a positive free cash flow trend in the latest year. The operating cash flow to net income ratio indicates strong cash generation relative to profits. However, previous periods showed negative free cash flow, pointing to potential challenges in managing capital expenditures effectively.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	41.59B	41.78B	41.36B	47.73B	49.49B	6.83B
Gross Profit	17.81B	16.07B	18.98B	20.44B	19.56B	1.37B
EBITDA	5.91B	5.57B	4.56B	5.81B	8.63B	1.07B
Net Income	2.78B	2.51B	1.83B	3.08B	4.77B	543.59M
Balance Sheet
Total Assets	0.00	50.32B	47.32B	42.59B	37.97B	33.79B
Cash, Cash Equivalents and Short-Term Investments	1.15B	1.15B	828.36M	1.08B	454.69M	1.17B
Total Debt	0.00	7.64B	7.40B	4.07B	2.38B	5.56B
Total Liabilities	-29.27B	21.05B	19.94B	15.93B	13.64B	14.56B
Stockholders Equity	29.27B	29.27B	27.37B	26.66B	24.33B	19.23B
Cash Flow
Free Cash Flow	0.00	1.42B	-1.38B	-189.30M	2.23B	847.36M
Operating Cash Flow	0.00	5.08B	4.30B	4.62B	4.53B	1.12B
Investing Cash Flow	0.00	-3.93B	-5.70B	-4.72B	-718.56M	-436.55M
Financing Cash Flow	0.00	-1.29B	1.44B	416.00M	-4.18B	-723.65M

Jubilant Ingrevia Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 726.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Positive. The current price of 726 is above the 20-day moving average (MA) of 704.71, above the 50-day MA of 698.22, and above the 200-day MA of 706.99, indicating a bullish trend. The MACD of 9.97 indicates Negative momentum. The RSI at 62.77 is Neutral, neither overbought nor oversold. The STOCH value of 74.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JUBLINGREA.

Jubilant Ingrevia Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMIORG	71 Outperform	₹138.19B	61.70	―	0.09%	34.62%	126.53%
ANURAS	66 Neutral	₹148.15B	95.37	―	0.06%	69.32%	113.55%
PRIVISCL	64 Neutral	₹105.30B	39.47	―	0.15%	24.25%	96.45%
JUBLINGREA	63 Neutral	₹109.29B	37.58	―	0.74%	3.80%	64.94%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ALKYLAMINE	61 Neutral	₹79.67B	43.73	―	0.62%	3.95%	8.28%
SUDARSCHEM	49 Neutral	₹74.19B	133.90	―	0.46%	159.81%	-63.02%

Jubilant Ingrevia Ltd. Corporate Events

Jubilant Ingrevia to Participate in Midcap Conference 2025

Jubilant Ingrevia Limited has announced its participation in the upcoming Midcap Conference 2025, scheduled for November 21, 2025, at the Grand Hyatt in Mumbai. The company will engage with investors and analysts through group and one-on-one meetings, sharing insights based on publicly available information. This participation underscores Jubilant Ingrevia’s commitment to transparency and investor engagement, potentially enhancing its market visibility and stakeholder relations.

Jubilant Ingrevia Releases Financial Performance Transcript for Q2 2025

Jubilant Ingrevia Ltd. has released a transcript of its investors’ conference call discussing the unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025. The release provides insights into the company’s financial performance and operational strategies, highlighting its commitment to transparency and engagement with stakeholders.